Revenue of the digestives & intestinal remedies industry in the Philippines 2018-2027

Published by Statista Research Department, Jun 1, 2023

The revenue in the digestives & intestinal remedies segment of the OTC pharmaceuticals market in the Philippines was forecast to continuously increase between 2023 and 2027 by in total 38.8 million U.S. dollars (+17.85 percent). After the fourth consecutive increasing year, the revenue is estimated to reach 256.07 million U.S. dollars and therefore a new peak in 2027. Notably, the revenue of the digestives & intestinal remedies segment of the OTC pharmaceuticals market was continuously increasing over the past years.

Find other key market indicators concerning the digestives & intestinal remedies segment of the OTC pharmaceuticals market in the Philippines, such as average revenue per user (ARPU) and revenue growth.

Revenue of the digestives & intestinal remedies market in the Philippines from 2018 to 2027 (in million U.S. dollars)

Characteristic	Revenue in million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

The Digestives and Intestinal Remedies segment comprises over-the-counter natural and synthetic digestive agents and remedies against gastrointestinal complaints. Digestives include preparations in the form of pills, powder, capsules, liquids, solutions, suspensions, drops and suppositories. Not included are prescription medicines, preparations that are against the state law or are not explicit digestive drugs (e.g. painkillers). Among the top-selling digestives are Perenterol, Iberogast, Dulcolax and Buscopan Plus. It includes both products which are exclusively sold in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Citation formats